ask our doctors

Chronic Myelogenous Leukemia

Get the facts on Chronic Myelogenous Leukemia treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Chronic Myelogenous Leukemia prevention, screening, research, statistics and other Chronic Myelogenous Leukemia related topics. We answer all your qestions about Chronic Myelogenous Leukemia.

Question: I have just been diagosed with chronic myelogenous leukemia.? I have just been diagosed with chronic myelogenous leukemia. I also just had a baby 3 weeks ago. What are the chances that she that or a similar bleeding disorder? I have not been exposed to any radiation. It actually came from a previous diagnosis, or perhaps a mis diagnosis (?) of Disseminated Intravascular Coagulation (DIC) a blood disorder that has some of the same symptoms and the potential to go into a form of leukemia if it is not treated or incorrectly treated.

Answer: CML is NOT hereditary; it is an acquired problem. Historically it was difficult to control long-term, as it transformed into acute leukemia (blast crisis). Currently, a new class of drugs (tyrosine kinase inhibitors) have transformed the treatment; most patients are placed into a molecular remission by one of these drugs, meaning that to the best of our ability we cannot detect evidence for the disease. Does it mean cure? Not sure yet, but maybe for some, or at least control of the disease for a long time(? for life, like high blood pressure- it is not cured, it is controlled). Acai berries have shown no such benefit as quoted above. They may taste good (or maybe not), but please don't put your faith in only that. DIC did not lead to or cause this; it is possible DIC could be caused by CML or its complications however. Given the way these drugs have transformed the care of CML patients, it is a time to be optimistic about future treatment and expectations. God bless, best wishes


Chronic Myelogenous Leukemia News

Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results

MarketWatch (press release)
... product candidate, BP-100-1.01 (Liposomal Grb-2), which is a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
 

U.S. News & World Report

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 ...
MarketWatch (press release)
 

Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be ...

MarketWatch (press release)
This trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblasatic leukemia (Ph + ALL) who are resistant or intolerant to either nilotinib or dasatinib, two currently available CML ...
 

Commentary: Join me in the fight against blood cancers

Daily Pilot
These advances include Gleevec, used for chronic myelogenous leukemia, Velcade for multiple myeloma, and Rituxan used primarily for non-Hodgkin's lymphoma. It is an honor and a privilege to be there for people affected by cancer.
 

Precision Medicine in the Care of Patients With Leukemia/Lymphoma

Cancer Network
[2] Death rates from lymphoma decreased by 16.85% between 1991 and 2007, and death rates for all types of leukemia combined decreased by 11.86%. Survival trends for chronic myelogenous leukemia (CML) in that same period improved by 18%.
 

The Origins of Leukemia

dailyRx
The research conclusively shows that two very different types of leukemia, chronic myelogenous leukemia, and B-Cell acute lymphoblastic leukemia, come from a mutation in the same type of cell, stem cells responsible for all blood production.
 

Nilotinib superior to imatinib in older patients with CML in chronic phase

Oncology Nurse Advisor
NEW ORLEANS?Nilotinib has superior safety and efficacy over imatinib in older patients with chronic myeloid leukemia in chronic phase, according to research presented at the Oncology Nursing Society (ONS) 37 th Annual Congress. Although chronic ...
 

Gleevec - $1.51 billion

FiercePharma
Gleevec is one of the revolutionary drugs that has transformed some blood cancers into chronic illnesses rather than death sentences. According to one study cited in Science Life, 5-year survival rates for patients with chronic myelogenous leukemia was ...
 

UK Health Body Approves Novartis's Tasigna For CML

Fox Business
LONDON ? The UK's health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from US-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the ...
 

Tim Holcomb's Battle With Leukemia

Sand Hills Express
What may not be as well known about Tim is his battle with Leukemia. Tim was diagnosed on May 12, 2003 with Chronic Myelogenous Leukemia and started treatments right away. After nearly 9 years of chemotherapy the doctors discovered that he had become ...